Brexpiprazole: Another multipurpose antipsychotic drug?

Journal of Psychosocial Nursing and Mental Health Services

Volumn 53, Issue 4, 2015, Pages 23-25

  Howland, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREXPIPRAZOLE; NEUROLEPTIC AGENT; QUINOLONE DERIVATIVE; THIOPHENE DERIVATIVE;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DEPRESSIVE DISORDER, MAJOR; HUMAN; PSYCHOMOTOR AGITATION; SCHIZOPHRENIA; STRESS DISORDERS, POST-TRAUMATIC;

ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DEPRESSIVE DISORDER, MAJOR; HUMANS; PSYCHOMOTOR AGITATION; QUINOLONES; SCHIZOPHRENIA; STRESS DISORDERS, POST-TRAUMATIC; THIOPHENES;

EID: 84937714818     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20150323-01     Document Type: Article

References (5)

1. Kane, J.M., Skuban, A., Ouyang, J., Hobart, M., Pfister, S., McQuade, R.D., Eriksson, H. (2015). A multicenter randomized doubleblind controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophrenia Research. Advance online publication. doi:10.1016/j.schres.2015.01.038
2. Maeda, K., Lerdrup, L., Sugino, H., Akazawa, H., Amada, N., McQuade, R.D., Kikuchi, T. (2014a). Brexpiprazole II: Antipsychotic-like and precognitive effects of a novel serotonindopamine activity modulator. Journal of Pharmacology and Experimental Therapeutics, 350, 605-614. doi:10.1124/jpet.114.213819
3. Maeda, K., Sugino, H., Akazawa, H., Amada, N., Shimada, J., Futamura, T., Kikuchi, T. (2014b). Brexpiprazole I: In vitro and in vivo characterization of a novel serotonindopamine activity modulator. Journal of Pharmacology and Experimental Therapeutics, 350, 589-604. doi:10.1124/jpet.114.213793
4. Otsuka Pharmaceutical. (2014, September 24). U.S. FDA accepts Otsuka and Lundbeck’s filing for review of brexpiprazole for the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression [Press release]. Retrieved from http://otsuka-us.com/newsroom/Pages/NewsArticle.aspx?ItemId=9
5. Thase, M., Youakim, J., Skuban, A., Hobart, M., Zhang, P., Legacy, S., Carson, W. (2014). Efficacy and safety of adjunctive brexpiprazole (OPC-34712) in major depressive disorder: Results of two pivotal clinical studies. Neuropsychopharmacology, 39, S357.